New drug cocktail shows promise for tough lung cancer mutation
NCT ID NCT05751187
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of four drugs—pembrolizumab, bevacizumab, pemetrexed, and cisplatin—as a first treatment for people with advanced non-squamous lung cancer that has a specific EGFR exon 20 insertion mutation. The study enrolled 54 participants and measures how many patients' tumors shrink or disappear. The goal is to find a more effective option for this hard-to-treat cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab, bevacizumab, pemetrexed, and cisplatin
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with a hard-to-treat form of lung cancer.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not be definitive. The combination also carries risks like immune-related side effects and bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.